ArticleThe World Allergy Organization journal2011
Interleukin-13 signaling and its role in asthma.
Article in The World Allergy Organization journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 199 citations in OpenAlex.
- Eosinophil Extracellular Traps in Health and Disease: From Host Defense to Chronic Inflammation.Biomedicines · 2026Review
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation.Journal of translational medicine · 2026Article
- Comparison of Tylophora indica with Tylophora pauciflora coupled with network pharmacology of phenanthroindolizidine alkaloids sheds light on its antiallergic potential.Molecular biology reports · 2026Article
- Real-World Identification of Eosinophilic COPD Patients Potentially Eligible for Dupilumab: A Retrospective Observational Study.International journal of chronic obstructive pulmonary disease · 2026Observational
- Shared Genetic Susceptibility Between Asthma and Immune-Mediated Inflammatory Diseases.Canadian respiratory journal · 2026Article
- Host Cell Protein Clinical Safety Risk Assessment-An Updated Industry Review.Biotechnology and bioengineering · 2025Review
- Anti-allergic and anti-inflammatory effects of Gastrodia elata Blume extract in ovalbumin-induced asthma rat model.Laboratory animal research · 2025Article
- Article
- Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?Pulmonary therapy · 2025Review
- Therapeutic effects of a combination ofFrontiers in nutrition · 2025Article
- FABIO: TWAS fine-mapping to prioritize causal genes for binary traits.PLoS genetics · 2024Article
- Immunogenicity and Protective Efficacy of Baculovirus-Expressed SARS-CoV-2 Envelope Protein in Mice as a Universal Vaccine Candidate.Vaccines · 2024Article
- Non-human peptides revealed in blood reflect the composition of intestinal microbiota.BMC biology · 2024Article
- Analysis of intracellular communication reveals consistent gene changes associated with early-stage acne skin.Cell communication and signaling : CCS · 2024Article
- A study of inflammatory biomarkers in crystalline silica exposed rock drillers.International archives of occupational and environmental health · 2024Article
- Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis.Internal medicine (Tokyo, Japan) · 2024Article
- Analysis of Intracellular Communication Reveals Consistent Gene Changes Associated with Early-Stage Acne Skin.Research square · 2024Article
- The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis.Biomaterials and biosystems · 2024Review
- Different polarization and functionality of CD4+ T helper subsets in people with post-COVID condition.Frontiers in immunology · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma affects nearly 300 million people worldwide. The majority respond to inhaled corticosteroid treatment with or without beta-adrenergic agonists. However, a subset of 5 to 10% with severe asthma do not respond optimally to these medications. Different phenotypes of asthma may explain why current therapies show limited benefits in subgroups of patients. Interleukin-13 is implicated as a central regulator in IgE synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. Promising research suggests that the interleukin-13 pathway may be an important target in the treatment of the different asthma phenotypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.